The threat of AMR has long been hailed as the greatest threat that the medical industry will face over the coming years. In the next issue of Pharma Technology Focus, we take a look at notable research projects that are trialling potential alternatives to traditional antibiotics.
Plus, we highlight the best and brightest players in regenerative medicine – including the likes of Humacyte, Frequency and Sigilon Therapeutics – and investigates the extent to which these innovations are ready for the pharma mainstream.
Elsewhere, we talk to hVIVO about concerns surrounding human challenge studies and ask whether their use in the pandemic could support further use of this novel trial approach, and examine the benefits and challenges of digitalising drug dispensing.
Plus, we speak to Novartis biomedical research president Jay Bradner about the development of a potentially groundbreaking treatment for sickle cell disease, and find out the unorthodox business model of Centessa Pharmaceuticals.
Editor | Eloise McLennan
Commissioning Editor | Daniel Garrun
Writers | Allie Nawrat, Chris Lo, Abi Millar, Chloe Kent, Alf Goebel
Magazine Designer | Marzia Del Gaone
Graphic Designers | Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Petra Konyi-Kiss, Maria Gimenez, Filipe Costa, Martina Labaiova
Lead Designer | John Hammond
Publisher | Susanne Hauner
Digital Publishing Director | Duncan West
Sales Manager | Nimai Amin
+44 (0) 207 936 6453
Pharma Technology focus is powered by h5mag
read past issues of pharma technology focus HERE
Copyright 2021 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.